Consultant Haematologist (Clinical and Laboratory) with a special interest in Paediatric Haematopoietic Stem Cell transplantation

Job title:

Consultant Haematologist (Clinical and Laboratory) with a special interest in Paediatric Haematopoietic Stem Cell transplantation

Company:

Children’s Health Ireland

Job description

Who We Are:(CHI) is leading on the clinical and operational transformation of acute paediatric healthcare and consists of hospitals at Crumlin, Temple Street and Tallaght as well as an Urgent Care Centre at Connolly hospital in Blanchardstown.Description:Scope of the Role:The National Children’s Cancer Service (NCCS) at Children’s Health Ireland (CHI) , Crumlin provides diagnosis and treatment to all children and adolescents (0–15 yrs, 364 days) with cancer in Ireland. This comprises those with solid tumors and those with haematological malignancies. The NCCS also incorporates the National Centre for Paediatric haematopoietic stem cell transplantation(HSCT) plus cellular therapies (CT) and is aligned with the National Cancer Control Programme (NCCP).The activity of the NCCS has significantly increased in both size and complexity over the past number of years. Comprehensive care for children and adolescents with cancer is delivered by robust clinically governed programmes and patient pathways. Treatment for paediatric leukaemia and lymphoma is planned according to internationally recognised best practice, and is delivered according to international treatment protocols. The majority of patients with Haematological Malignancies are enrolled on clinical trials and treatment is delivered by robust clinically governed programmes. This requires on-going collaborative discussions at MDT level with other CCLG centres.There are on average 80 new blood cancer diagnoses per year, making CHI at Crumlin one of the largest centres for haematological malignancies in Europe and the second largest contributor to the UK Children’s Cancer and Leukaemia Group clinical trials over the past two decades. Between 1975 and 2017, the number of deaths from cancer in children decreased by greater than 50%. This is directly due to participation in clinical trials and advances in treatment that have changes the therapeutic landscape for treatment of these diseases. Despite these advances, relapsed leukaemia remains the leading cause of cancer death in children. The majority of CHI cancer patients are treated as part of international multicentre clinical trials, which now incorporate increasingly complex diagnostic algorithms and risk stratifications based on new molecular methodologies of disease measurement and laboratory techniques, including measurable residual disease analysis (MRD) and next generation sequencing (NGS). Relapsed disease has now several therapeutic options including immunotherapies as well as chemotherapy. The latest clinical trials also comprise novel sophisticated treatment modalities (immunotherapy/CART cells) that increase the complexity of monitoring treatment responses.The NCCS at CHI Crumlin is a tertiary referral centre for cancer in children. It is a comprehensive cancer treatment centre, a model supported by the NCCP. All diagnostic work and therapeutic interventions are carried out here. There is a 19-bed in-patient unit and an 8-bed Day unit for ambulatory care. These resources are shared with Oncology. HSCT and CT has evolved as a complex and distinct sub-specialty within Haematology, encompassing medical and scientific disciplines including stem cell biology, transplantation immunology, oncology, haematology, genetics and infectious diseases.The HSCT programme at CHI at Crumlin began in 1982, it is accredited by the Joint Accreditation Committee for the International Society of Cellular Therapy and European Bone Marrow Transplantation (JACIE) since 2014. CHI Crumlin has its own Tissue Establishment and is licenced by the Health Products Regulatory Authority (HPRA) to process and manipulate stem cells on site. The HSCT Service at CHI at Crumlin delivers over 30 allogeneic and autologous transplants annually. Chimeric Antigen Receptor (CAR)-T Programme was recently established at CHI, Crumlin.Eligibility CriteriaProfessional Qualifications and ExperienceMandatory:a) Registration as a specialist in the Specialist Division of the Register of Medical Practitioners maintained by the Medical Council in Ireland in the specialty of Haematology (clinical and laboratory) or entitlement to be registeredAndb) One year documented postgraduate evidence of training and/or experience assuring competence in paediatric haematology.Competition Specific Selection ProcessThe criteria for short listing are based on the requirements of the post as outlined in the eligibility criteria and/or the essential & desirable knowledge, skills and competencies section of this job specification.Failure to include information regarding these requirements may result in you not being called forward to the next stage of the selection processTo apply for this position, please send a CV and letter of application.The closing date for submissions of CV’s and letter of application is 11:30pm on Sunday May 25th 2025. Applications must be completed through the advertised post on CHI.jobsby clicking ‘Apply for Job’.Applications will not be accepted through direct email or any other method.Informal Enquiries can be obtained from:Professor Owen Smith, consultant haematologist Children’s Health Ireland, owensmith62@me.com or 00353872484111For other queries relating to this recruitment process, please contact Cillian Greene, HR Recruitment Specialist atSkills and attributes:

• Haematology
• IMC Specialist Registration
• Transplant

Expected salary

Location

Dublin

Job date

Wed, 09 Jul 2025 23:22:51 GMT

To help us track our recruitment effort, please indicate in your email/cover letter where (vacanciesin.eu) you saw this job posting.